These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16445828)

  • 1. cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy.
    Valente G; Manfroi F; Peracchio C; Nicotra G; Castino R; Nicosia G; Kerim S; Isidoro C
    Br J Haematol; 2006 Mar; 132(5):560-70. PubMed ID: 16445828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
    Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in expression of anti-apoptotic protein, cFLIP, in granulosa cells during follicular atresia in porcine ovaries.
    Matsuda-Minehata F; Goto Y; Inoue N; Manabe N
    Mol Reprod Dev; 2005 Oct; 72(2):145-51. PubMed ID: 16010689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and grading of non-Hodgkin's lymphomas on fine needle aspiration cytology.
    Mathur S; Dawar R; Verma K
    Indian J Pathol Microbiol; 2007 Jan; 50(1):46-50. PubMed ID: 17474258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways.
    de Hooge AS; Berghuis D; Santos SJ; Mooiman E; Romeo S; Kummer JA; Egeler RM; van Tol MJ; Melief CJ; Hogendoorn PC; Lankester AC
    Clin Cancer Res; 2007 Jan; 13(1):206-14. PubMed ID: 17200356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of cellular FLICE inhibitory protein (cFLIP) in endometrial adenocarcinoma].
    Chen HX; Liu YJ; Li H; Wang ZS
    Ai Zheng; 2004 Mar; 23(3):254-8. PubMed ID: 15025952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MIB1 (Ki-67) expression in non-Hodgkin's lymphomas.
    Kalogeraki A; Tzardi M; Panagiotides I; Koutsoubi K; Bolioti S; Rontogianni D; Stefanaki K; Zois E; Karidi E; Darivianaki K; Delides G; Kanavaros P
    Anticancer Res; 1997; 17(1A):487-91. PubMed ID: 9066700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nucleolar organizer as a marker of malignancy grade and prognosis of non-Hodgkin's malignant lymphoma].
    Raĭkhlin NT; Bukaeva IA; Probatova NA; Smirnova EA; Tupitsyn NN; Sholokhova EN
    Arkh Patol; 1996; 58(4):22-8. PubMed ID: 8967858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caspase-8 and its inhibitors in RCCs in vivo: the prominent role of ARC.
    Heikaus S; Kempf T; Mahotka C; Gabbert HE; Ramp U
    Apoptosis; 2008 Jul; 13(7):938-49. PubMed ID: 18516683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas.
    Szczuraszek K; Mazur G; Jeleń M; Dziegiel P; Surowiak P; Zabel M
    Anticancer Res; 2008; 28(2A):1113-8. PubMed ID: 18507062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of procaspase-3 and its clinical significance in childhood non-Hodgkin lymphomas.
    Wrobel G; Maldyk J; Kazanowska B; Rapala M; Maciejka-Kapuscinska L; Chaber R
    Pediatr Dev Pathol; 2011; 14(3):173-9. PubMed ID: 20722551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AgNORs predictive value of prognosis in non-Hodgkin's lymphoma according to the Kiel classification.
    Jakić-Razumović J; Petrovecki M; Dominis M
    Mod Pathol; 1995 Feb; 8(2):143-9. PubMed ID: 7777474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Malignant non-Hodgkin's lymphoma of the joint. Report of two cases, review of the literature and problems of classification].
    Krüger R; Oden J; de Leon F; Dürr W
    Unfallchirurg; 1993 Oct; 96(10):556-62. PubMed ID: 8235678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-apoptotic activity of porcine cFLIP in ovarian granulosa cell lines.
    Matsuda-Minehata F; Goto Y; Inoue N; Sakamaki K; Chedrese PJ; Manabe N
    Mol Reprod Dev; 2007 Sep; 74(9):1165-70. PubMed ID: 17594695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma.
    Dutton A; Burns AT; Young LS; Murray PG
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):911-9. PubMed ID: 16761935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.